Science News
from research organizations
Vismodegib in basal cell carcinoma: Added benefit not proven
- Date:
- November 19, 2013
- Source:
- Institute for Quality and Efficiency in Health Care
- Summary:
- No added benefit was found with the use of the drug Vismodegib versus the appropriate comparator therapy in a study focused on basal cell carcinoma.
- Share:
FULL STORY
The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma (BCC): symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.
Story Source:
Materials provided by Institute for Quality and Efficiency in Health Care. Note: Content may be edited for style and length.
Cite This Page:
Institute for Quality and Efficiency in Health Care. "Vismodegib in basal cell carcinoma: Added benefit not proven." ScienceDaily. ScienceDaily, 19 November 2013. <www.sciencedaily.com
Institute for Quality and Efficiency in Health Care. (2013, November 19). Vismodegib in basal cell carcinoma: Added benefit not proven. ScienceDaily. Retrieved August 31, 2025 from www.sciencedaily.com
Institute for Quality and Efficiency in Health Care. "Vismodegib in basal cell carcinoma: Added benefit not proven." ScienceDaily. www.sciencedaily.com
Explore More
from ScienceDaily
RELATED STORIES